MENS Jyong Biotech Ltd. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1954488
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-54.7%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-34.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets219.9%
Debt / equity—
Current ratio0.45x
Interest coverage-1.03x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $813,000 | $927,000 | $1.07M |
| SG&A expense | $1.75M | $1.08M | $1.68M |
| Operating income | -$2.61M | -$2.06M | -$2.80M |
| Interest expense | $2.54M | $1.03M | $757,000 |
| Pretax income | -$4.67M | -$3.02M | -$4.40M |
| Net income | -$4.67M | -$3.02M | -$4.40M |
| EBITDA | -$2.51M | -$1.94M | -$2.67M |
| EPS (basic) | -0.06 | -0.04 | -0.06 |
| EPS (diluted) | -0.06 | -0.04 | -0.06 |
| Weighted avg. shares (diluted) | 73.01M | 71.57M | 71.57M |
| Balance sheet | |||
| Cash & equivalents | $1.18M | $101,000 | $1.74M |
| Current assets | $15.54M | $206,000 | — |
| PP&E, net | $3.09M | $3.05M | — |
| Total assets | $20.78M | $6.37M | — |
| Current liabilities | $34.81M | $12.13M | — |
| Short-term debt | $15.34M | — | — |
| Long-term debt | $2.12M | — | — |
| Total debt | $17.46M | — | — |
| Total liabilities | $45.68M | $42.88M | — |
| Shareholders' equity | -$24.91M | -$36.52M | -$34.07M |
| Net debt | $16.28M | — | — |
| Shares outstanding | 76.03M | 73.36M | — |
| Cash flow statement | |||
| Operating cash flow | -$3.04M | -$3.62M | -$2.60M |
| Investing cash flow | -$13.51M | — | $95,000 |
| Financing cash flow | $17.63M | $1.99M | $2.03M |
| Depreciation & amortization | $100,000 | $120,000 | $127,000 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.